Arca
Skip to content
Tools
Tools

KLKB1: Plasma kallikrein

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Participates in the surface-dependent activation of blood coagulation.

  • Drugs that act on it: 6
  • Approved: 5
  • In phases 1 to 3: 1
  • Sponsors: 4

Who Is On It, and How Far Along

Every drug ChEMBL records acting on KLKB1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody
  • Protein or peptide
  • Other

Approved5

  • Human C1-ESTERASE inhibitor
  • Lanadelumab
  • Aprotinin
  • Berotralstat
  • Ecallantide

Phase 31

  • Avoralstat

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule233%
      • Antibody117%
      • Protein or peptide233%
      • Other117%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Plasma kallikrein inhibitor.
      Human C1-ESTERASE inhibitorApprovedIMMUNOe Research CentersProtein or peptideInhibitor—5—
      LanadelumabApprovedTakeda Pharmaceuticals USAAntibodyInhibitor—3—
      AprotininApprovedBayerOtherInhibitor—2Withdrawn
      BerotralstatApprovedBioCryst PharmaceuticalsSmall moleculeInhibitor—2—
      EcallantideApprovedTakeda Pharmaceuticals USAProtein or peptideInhibitor—0Boxed warning
      AvoralstatPhase 3BioCryst PharmaceuticalsSmall moleculeInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 12 in all, from ClinicalTrials.gov.
      Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious PathogensHuman C1-ESTERASE inhibitorPhase 4RecruitingIMMUNOe Research Centers2026-11-12
      A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South KoreaLanadelumab—RecruitingTakeda2026-03-03
      New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome.AprotininNot applicableNot yet recruitingUniversity Hospital, Rouen2026-01-13
      Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome TreatmentAprotininPhase 3RecruitingFundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion2026-01-05
      Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)Human C1-ESTERASE inhibitorPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)2025-04-09
      Lanadelumab in Long-term Prophylaxis of Acquired AngioedemaLanadelumabPhase 4RecruitingBernstein Clinical Research Center2025-02-10
      Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksHuman C1-ESTERASE inhibitorPhase 3RecruitingOctapharma2024-04-12
      Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)Human C1-ESTERASE inhibitorPhase 2RecruitingHaaglanden Medical Centre2024-04-11
      A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)Lanadelumab—Active, not recruitingTakeda2022-07-22
      Berotralstat Treatment in Children With Hereditary AngioedemaBerotralstatPhase 3Active, not recruitingBioCryst Pharmaceuticals2022-07-12
      A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaHuman C1-ESTERASE inhibitorPhase 1 / Phase 2Active, not recruitingBioMarin Pharmaceutical2021-11-16
      Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesBerotralstatPhase 3Enrolling by invitationBioCryst Pharmaceuticals2021-06-22

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Inherited prekallikrein deficiency
      0.72
      Prekallikrein deficiency
      0.67
      Blood coagulation disease
      0.51
      Serum lipopolysaccharide activity
      0.42
      Heart disorder
      0.41
      Hemorrhagic disease
      0.37
      Cardiovascular disorder
      0.36
      Coronary artery calcification
      0.36

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2000, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P03952, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.